Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

Frank Giles, MD MB, FRCPI, FRCPath, Sarina A. Piha-Paul, MD, Alexander I. Spira, PhD MD FACP, Fadi Braiteh, MD CPI, Julio Antonio Peguero, MD, Daniel L. Spitz, MD FACP, James A. Knost, MD, Lee Schwartzberg, MD FACP, Steven Stein, MD, August J. Salvado, MD, Claudia Lebedinsky, MD, Barinder Kang, PhD, Eric Slosberg, PhD

Blood (2014) 124 (21): 4818.

https://doi.org/10.1182/blood.V124.21.4818.4818

Published: 2014

Journal Articles

No Evidence Of Increased Cyclophosphamide Toxicity Associated With The Antiemetic Agent NEPA, a Fixed-Dose Combination Of Netupitant and Palonosetron

Lee Schwartzberg, MD, FACP, Cristina Oprean, MD, Servando Cardona-Huerta, MD, Giada Rizzi, M.Sc., Giorgia Rossi, MD, Marco Palmas, MD, Meinolf Karthaus, MD, Matti Aapro, MD

Blood (2013) 122 (21): 2949.

https://doi.org/10.1182/blood.V122.21.2949.2949

Published: 2013

Journal Articles

Phase II Study of Enzastaurin in Patients with Follicular Lymphoma: Updated Final Clinical Results and Immunohistochemical Correlations

Lee Schwartzberg, MD, FACP, Robert Hermann, MD FACP, Ian W. Flinn, MD, PhD, Douglas Flora, MD, Eric D. Hsi, MD, Oday Hamid, Scott P. Myrand, BSc, MSc, MBA, Boris Lin, MD, PhD, Donald Thornton, MD, Peipei Shi, Ph.D., Tuan S Nguyen, Ph.D., Martin Dreyling

Blood (2012) 120 (21): 777.

https://doi.org/10.1182/blood.V120.21.777.777

Published: 2012

Journal Articles

Ad-ISF35-Transduced Autologous Cells In Combination with Fludarabine, Cyclophosphamide, Rituximab (FCR) Induces Complete and Partial Responses In a Phase 1b Study for Patients with Fludarabine-Refractory and/or Del(17p)/p53-Defective Chronic Lymphocytic Leukemia (CLL)

Januario E. Castro, M.D., Lee Schwartzberg, MD, FACP, Javier Pinilla-Ibarz, MD, PhD, Johanna Melo-Cardenas, B.Sc, Juan S. Barajas-Gamboa, M.D., Mark J. Cantwell, PhD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 168.

https://doi.org/10.1182/blood.V118.21.168.168

Published: 2011

Journal Articles

A Phase 2, Randomized, Open-Label Study To Assess the Efficacy of Extended Dose Schedule Administration of Darbepoetin Alfa (DA) in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA).

Lee Schwartzberg, MD, Timothy Rearden, MD, Lorrin Yee, MD, Barry Mirtsching, MD, Veena Charu, MD, Hung Lam, PhD, Tom Lillie, MD/PhD, Ronald Burkes, MD, Peter Silberstein, MD

Blood (2006) 108 (11): 1306.

https://doi.org/10.1182/blood.V108.11.1306.1306

Published: 2006

Journal Articles

A Phase 2 Study of the Thrombospondin-Mimetic Peptide ABT-510 in Patients with Refractory Lymphoma.

Alexandra M. Levine, MD, Lee Schwartzberg, MD, Sonali Smith, MD, Robert Belt, Raymond Knight, Dawn Carlson, Richard Hippensteel, Brad Kahl

Blood (2005) 106 (11): 1493.

https://doi.org/10.1182/blood.V106.11.1493.1493

Published: 2005

NARROW

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

No Evidence Of Increased Cyclophosphamide Toxicity Associated With The Antiemetic Agent NEPA, a Fixed-Dose Combination Of Netupitant and Palonosetron

Phase II Study of Enzastaurin in Patients with Follicular Lymphoma: Updated Final Clinical Results and Immunohistochemical Correlations

Ad-ISF35-Transduced Autologous Cells In Combination with Fludarabine, Cyclophosphamide, Rituximab (FCR) Induces Complete and Partial Responses In a Phase 1b Study for Patients with Fludarabine-Refractory and/or Del(17p)/p53-Defective Chronic Lymphocytic Leukemia (CLL)

A Phase 2, Randomized, Open-Label Study To Assess the Efficacy of Extended Dose Schedule Administration of Darbepoetin Alfa (DA) in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA).

A Phase 2 Study of the Thrombospondin-Mimetic Peptide ABT-510 in Patients with Refractory Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

No Evidence Of Increased Cyclophosphamide Toxicity Associated With The Antiemetic Agent NEPA, a Fixed-Dose Combination Of Netupitant and Palonosetron

Phase II Study of Enzastaurin in Patients with Follicular Lymphoma: Updated Final Clinical Results and Immunohistochemical Correlations

Ad-ISF35-Transduced Autologous Cells In Combination with Fludarabine, Cyclophosphamide, Rituximab (FCR) Induces Complete and Partial Responses In a Phase 1b Study for Patients with Fludarabine-Refractory and/or Del(17p)/p53-Defective Chronic Lymphocytic Leukemia (CLL)

A Phase 2, Randomized, Open-Label Study To Assess the Efficacy of Extended Dose Schedule Administration of Darbepoetin Alfa (DA) in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA).

A Phase 2 Study of the Thrombospondin-Mimetic Peptide ABT-510 in Patients with Refractory Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only